Found: 6
Select item for more details and to access through your institution.
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial Re LApsE.
- Published in:
- European Journal of Haematology, 2017, v. 99, n. 1, p. 42, doi. 10.1111/ejh.12888
- By:
- Publication type:
- Article
Impact of cytogenetics at relapse on prognosis and benefit from salvage autologous stem cell transplantation in the GMMG phase III trial ReLApsE.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e286, doi. 10.1016/j.clml.2019.09.471
- By:
- Publication type:
- Article
Comparison of bortezomib versus lenalidomide maintenance therapy in newly-diagnosed, transplant-eligible multiple myeloma: Results from the phase III GMMG-HD4 and -MM5 trials.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e43, doi. 10.1016/j.clml.2019.09.065
- By:
- Publication type:
- Article
Response After Induction Therapy in Transplant-eligible Newly-diagnosed Myeloma - a Pooled Analysis from Three Subsequent Multicenter Phase III Trials.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e76, doi. 10.1016/j.clml.2017.03.137
- By:
- Publication type:
- Article
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41408-020-00390-3
- By:
- Publication type:
- Article
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
- Published in:
- 2016
- By:
- Publication type:
- journal article